Recombinant Human CCL17 Protein (C-6His)

Name: Recombinant Human CCL17 Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0565NP
Availability: InStock

BL-0565NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Chemokines and receptors, Cytokines, Cytokines and growth factors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human C-C Motif Chemokine 17 is produced by our Mammalian expression system and the target gene encoding Ala24-Ser94 is expressed with a 6His tag at the C-terminus.
Accession	Q92583
Synonym	ABCD-2; CC chemokine TARC; C-C motif chemokine 17; CCL17; chemokine (C-C motif) ligand 17; MGC138273; SCYA17MGC138271; small inducible cytokine subfamily A (Cys-Cys), member 17; Small-inducible cytokine A17; T cell-directed CC chemokine; TARC; TARCA-152E5.3; Thymus and activation-regulated chemokine
Gene Background	C-C motif chemokine 17 (CCL17) is a novel CC chemokine, it belongs to the intercrine beta (chemokine CC) family. CCL17 is expressed at high levels in thymus, and at a lower level in lung, colon, and small intestine. CCL17 is also transiently expressed in stimulated peripheral blood mononuclear cells. Among CC chemokine family members, CCL17 has approximately 24 - 29% amino acid sequence identity with RANTES, MIP-1 alpha, MIP-1 beta, MCP-1, MCP-2 and MCP-3. CCL17 has been identified to be Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. CCL17 plays a role in T-cell development in thymus and in trafficking and activation of mature T-cells.
Molecular Mass	9.1 KDa
Apmol Mass	13 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.
Subcellular Location	Secreted.
Protein Families	Intercrine beta (chemokine CC) family
Database References	HGNC: 10615 OMIM: 601520 KEGG: hsa:6361 STRING: 9606.ENSP00000219244 UniGene: Hs.546294
Tissue Specificity	Expressed at high levels in thymus and at low levels in the lung, colon and small intestine.

Gene Functions References

The frequency of the CC genotype in the TARC rs223828 SNP was higher in patients with intractable Graves disease than in patients with Graves disease in remission. PMID: 29848886
The expression of CCL17 was decreased in nasal polyp (NP) epithelium compared to the epithelium of normal ethmoid sinus, whereas the expression of CCL22 was not decreased. E-cadherin was differentially distributed between the epithelium of normal ethmoid sinus and NP epithelium. EGFR was also decreased in NPs. PMID: 29746583
TARC serum levels were elevated in 78% of sarcoidosis patients and correlated with disease severity. PMID: 29598931
Serum TARC level may be a potent marker reflecting better response to IL-17A inhibitors for psoriasis treatment. PMID: 29655215
This review presents key clinical studies of Multiple sclerosis together with experimental studies in animals that have demonstrated functional roles of CCR4, CCL17, and CCL22 in experimental autoimmune encephalomyelitis pathogenesis. [review] PMID: 29099057
Taken together, our data showed a likely positive feedback mechanism of enhanced IL-6 production in ectopic milieu. The high levels of IL-6 in the peritoneal cavity stimulate the expression of CCL17 in endometrial stromal cells by activating JNK signal pathway, and then, CCL17 further induces CCR4 expression on macrophages, which eventually leads to an increase in IL-6 production via NF-kappaB activation. PMID: 28240436
Data suggest that high levels of CCL17 and CCL22 in endometrium in women with endometriosis promote (1) recruitment of Tregs, (2) immunosuppression of Tregs, and (3) angiogenesis in endometrium. (Tregs = regulatory T cells) PMID: 28383711
Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions. PMID: 28648978
TARC production in HaCaT keratinocytes through the interaction between IL-22 and IL-22Ralpha facilitates T-cell migration in atopic dermatitis caused by house dust mites. PMID: 26914146
TARC is a candidate biomarker for PTSD only in males. PMID: 28170001
High CCL17 expression is associated with colon cancer cell migration. PMID: 28146427
GM-CSF can mediate inflammation and pain by regulating IRF4-induced CCL17 production PMID: 27525438
Based on the ADEPT study data set, we report that airway mucosal expression of CCL26 was a robust discriminator of type 2 inflammation from healthy nonatopic subjects. Furthermore, airway mucosal CCL26 expression was best identified by using a panel of clinical biomarkers, including Feno values, bEOS counts, and expression of 2 novel markers, sCCL17 and sCCL26 PMID: 28089872
Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with clear cell renal cell carcinoma after nephrectomy. PMID: 28178948
IP-10 serum increase or TARC/IP-10 ratio decrease along with abnormal hepatic enzymatic alteration could signify early rejection of the transplanted liver. PMID: 28245475
elevated pre-treatment levels of sGal-1, sCD163, sCD30 and TARC can be found in patients with classic Hodgkin lymphoma. However, only plasma TARC accurately reflects disease activity and correlates with clinical treatment response. PMID: 27610595
levels elevated in rheumatoid arthritis synovial fluid, due to production by mononuclear cells, particularly CD1c classical dendritic cells PMID: 27250804
Serum TARC levels are well correlated with blood eosinophil counts in patients with generalized drug eruptions, indicating that Th2-type immune reactions underlie TARC production. Serum TARC measurements also have potent diagnostic value for DIHS, with high sensitivity and specificity. PMID: 27497618
Data suggest that Th1 (IFN-gamma-inducible protein-10 IP-10/CXCL10) and Th2 (thymus and activation regulated chemokine TARC/CCL17) and (macrophage derived chemokine MDC/CCL22) cooperatively play a role in the development of ankylosing spondylitis (AS). PMID: 26827189
CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma.Higher levels of intratumoral CCL17 expression are associated with poorer survival of hepatocellular carcinoma patients. PMID: 26781124
CCL17 and CCL18 dermal expression is associated with leprosy polarity. PMID: 25412496
The SNP rs223895 in TARC/CCL17 gene is associated with the susceptibility to Kawasaki disease. PMID: 26182268
Serum CCL17 levels are associated with coronary artery disease and atherosclerosis severity independently of traditional cardiovascular risk factors. PMID: 25555269
TARC was correlated with disease status and its monitoring may be able to predict PET positivity after alloSCT, thus potentially allowing an early immune manipulation. PMID: 25240818
Serum levels of CCL17 were positively correlated with coronary artery disease. PMID: 25062565
increased expression in the thymus of myasthenia gravis patients PMID: 24397961
TARC and interleukin-31 may be biomarkers for adult atopic dermatitis PMID: 24984931
Serum TARC is a promising biomarker for remission and can be used for accurately monitoring proactive treatment for long-term control. [revew] PMID: 24628072
disease activity and response biomarker in alopecia areata PMID: 24102731
High CXCL10 levels were detected in acutely infected children regardless of virus pathogen, whereas increased CCL17 production was RSV-specific PMID: 25013801
Higher serum concentrations of CCL17 at baseline may be predictive of acute exacerbations in patients with chronic hypersensitivity pneumonitis PMID: 23705860
might be potential marker of non-eosinophilic oesophagitis gastrointestinal food allergies PMID: 24698291
Serum TARC may represent a suitable biomarker for monitoring of atopic dermatitis severity in daily practice. PMID: 25199679
Although TARC and I-TAC may not directly regulate pruritus in atopic dermatitis patients, these chemokines are very sensitive disease markers of AD. PMID: 24104601
we found that TARC is an easily measured biomarker that is associated with faster TTR, longer PFS, and possibly longer OS in a population of patients with HL who were treated with panobinostat. PMID: 23822537
The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD PMID: 25268342
CCL17 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
An association between TARC/CCL17 polymorphisms, susceptibility of Kawasaki disease, and intravenous immunoglobulin responses in Kawasaki disease patients. PMID: 23942559
Migration assays were performed to evaluate CCL17-induced colon cancer cell (HT-29) chemotaxis and RhoA protein levels were quantified. PMID: 24582560
Ginseng inhibited TARC expression via blockade of NF-kappaB activation in HaCaT cells. PMID: 23454147
CCL17-induced, CCR4-dependent release of CGRP by human airway epithelial cells represents a novel inflammatory pathway in patients with asthma and allergic disease. PMID: 23731651
These data reveal an elevated serum concentration of Th2-attracting chemokines CCL22 and CCL17 in opsoclonus-myoclonus syndrome. PMID: 23340773
Autistic children had significantly higher serum levels of TARC than healthy controls PMID: 23782855
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. PMID: 23224400
Data suggest an important role for serum CCL17 level as biomarker of drug resistance/remission induction in Hodgkin lymphoma in response to various combined neoplastic agent protocols. PMID: 23225085
increased expression in macrophages from asthmatic patients PMID: 22981793
Data show that PD-1, PD-L1, PD-L2, CCL17, and CCL22 mRNA was identified in papillomas. PMID: 22322668
Serum concentrations of TARC and CTACK were significantly higher in AD (atopic dermatitis) children than in healthy controls, and correlated with severity of symptoms. PMID: 22017510
Baseline plasma thymus and activation-regulated chemokine levels correlate with classical Hodgkin's lymphoma tumor burden and serial levels correlate with response to treatment in patients with classical Hodgkin's lymphoma. PMID: 22058214
PI16-positive Treg showed enhanced in vitro migration towards the inflammatory chemokines CCL17 and CCL20, suggesting they can migrate to sites of inflammation PMID: 22533972

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.